CDK2 and pancreatic neoplasm: As expected, the downregulation of TNFR2 in pancreatic cancer cells and anti-TNFR2 antibody decreased the levels of proteins in survival pathways, such as c-Myc, cyclin D and CDK2, and increased the levels of protein in apoptosis pathways, such as cleaved-caspase 3.